Automated Digital Pathology Device for High-Throughput Demand
Summary:
The NCI is seeking licensees to develop an automated digital pathology device compatible with high-throughput data analysis.
New Heterocyclic Scaffold-Based Inhibitors of the Polo-Box Domain of Polo-like Kinase 1 for the Treatment of Cancer
Summary:
The National Institutes of Health is seeking commercial partners to co-develop and/or license a heterocyclic scaffold for development of therapeutics against Plk1-dependent cancers.
Chimeric Antigen Receptors to CD22 for Treating Hematological Cancers
Description of Technology:
Chimeric antigen receptors (CARs) are hybrid proteins consisting of an antibody binding fragment fused to protein signaling domains that cause T-cells which express the CAR to become cytotoxic. Once activated, these cytotoxic T-cells can selectively eliminate the cells which they recognize via the antibody binding fragment of the CAR. Thus, by engineering a T-cell to express a CAR that is specific for a certain cell surface protein, it is possible to selectively target those cells for destruction. This promising new therapeutic approach
HIV-1 IN Mutant in a Single Round Vector
Summary:
The Retroviral Replication Laboratory of the National Cancer Institute actively seeks parties interested in non-exclusive licensing a collection of single-round vectors containing mutations in HIV-1 IN or RT.
Enhanced Cancer Chemotherapy Using the Bioactive Peptide Recifin And Its Analogues
Summary:
NCI seeks research co-development partners and/or licensees for the development of recifin and its analogues as new chemosensitizing agents in adjunct therapies with topotecan, irinotecan and related chemotherapeutic agents.
High-Throughput Generation of Induced Pluripotent Stem Cells Carrying Antigen-Specific T Cell Receptors from Tumor Infiltrated Lymphocytes
Summary:
NCI seeks proposals from parties interested in licensing an improved method for the identification of TCRs from bulk populations of TIL for the development of cancer immunotherapies.
Anti-Viral Polypeptide Griffithsin: Compounds, Compositions, and Methods of Use
Description of Technology:
This technology describes additional methods of using the griffithsin anti-viral polypeptides described in related NCI invention (reference number E-106-2003). Specifically, this invention describes the use of GRFT to inhibit viral infection of hepatitis C viral infection, a severe acute respiratory syndrome (SARS) viral infection, an H5N1 viral infection, or an Ebola viral infection.
Human and Improved Murine Monoclonal Antibodies Against CD22
Summary:
Researchers at the NCI seek research and co-development partners and/or licensing for the development of human monoclonal antibodies and antibody-based therapeutics against CD22.
Adjuvanted Mucosal Subunit Vaccines for Preventing SARS-CoV-2 Transmission and Infection
Summary:
Inventors are seeking licensing and/or co-development research collaborations for a unique novel molecular Adjuvanted Mucosal Subunit Vaccine to prevent SARS-CoV-2 transmission and infection.
AT-3 Mouse Breast Tumor Cell Line
Summary:
NCI is seeking licensees for the AT-3 mouse breast tumor cell line.